Network of experts join forces to fight myasthenia gravis

July 22, 2014 by Fiona Dunlevy,
Network of experts join forces to fight myasthenia gravis

Collaboration between research groups is key in tackling rare diseases such as auto-immune disease myasthenia gravis (MG). Indeed, the rarity of the disease means that it can be difficult to collect enough samples of blood and tissues to perform quality research. Let alone to recruit enough patients into clinical trials. To side step this problem, the EU funded project FIGHT-MG has established a network of 11 leading MG research groups in Europe.

This allows the team to tackle the disease from all angles and better understand the disconnect between the nervous and muscular systems by sharing resources and testing duties. This approach has had previous successes. For example, Sonia Berrih-Aknin, project coordinator, who is also director of research in immunology leading a team on MG at INSERM, in Paris, France, cites examples such as a recent multinational study on twins carried out in partner countries, and a Greek study that identified a new player in the disease using blood samples collected within the network.

Before developing new treatments, it is key to understand the mechanisms of the disease. "The immune system is quite complicated," says Berrih-Aknin, explaining that in MG the immune system is activated at many different levels. She believes that could modulate "all the different pathways of the immune system and could be much more efficient than the therapies available today." Although stem cell therapy has already been used to treat other diseases, this approach will not be without its challenges. "We have a lot of data showing that it is not sufficient to use the in a resting state but you have to condition them," says Berrih-Aknin, adding: "we will need to define very precisely how to do that."

Support from a network of leading researchers across Europe specialised in a rare auto-immune disease with unmet medical needs could help test several novel treatments.

One expert agrees. "As a treatment, cell-based therapies are in their infancy," says Henry Kaminski, professor of neurology, pharmacology and physiology at George Washington University, in Washington DC, USA. "The ability to grow cells uniformly across medical centres, the response of a diverse group of patients, and the potential adverse effects of these treatments will require a great deal of time and money to determine their ultimate therapeutic value," he tells

Another strategy Berrih-Aknin's team is taking is to use antibodies that very specifically target and block the action of key components implicated in MG. "We have done a lot of work on the pathophysiology of the disease and we have some specific targets," says Berrih-Aknin. Sara Fuchs, professor of neuro-immunology at the Weizmann Institute of Science, Rehovot, Israel, also believes monocloncal antibody therapy is "a very promising approach." She tells that "monoclonal antibody therapy may have less side-effects and be less costly than other available immuno-therapies such as cell therapy."

Ultimately, Berrih-Aknin believes her team has everything in place to have a treatment in within three years. "We have very good relevant models. The molecules that we would like to use are already on the market. We have strong consultation of patients behind the project and collaboration with physicians," she says.

Explore further: Auto-immune disease: The viral route is confirmed

Related Stories

Auto-immune disease: The viral route is confirmed

December 19, 2012
Why would our immune system turn against our own cells? This is the question that the combined Inserm/CNRS/ Pierre and Marie Curie University/Association Institut de Myologie have strived to answer in their "Therapies for ...

New possibilities for leukemia therapy with a novel mode of leukemia cell recognition

June 24, 2014
Scientists at A*STAR's Singapore Immunology Network (SIgN) have discovered a new class of lipids in the leukaemia cells that are detected by a unique group of immune cells. By recognising the lipids, the immune cells stimulate ...

Opening-up the stem cell niche

July 11, 2014
For many years scientists have been trying to unravel mechanisms that guide function and differentiation of blood stem cells, those cells that generate all blood cells including our immune system. The study of human blood ...

A vaccine may cause pancreatic cancer to respond to immunotherapy

July 10, 2014
(Medical Xpress)—Pancreatic ductal adenocarcinomas (PDAC) do not typically respond to immunotherapy, which limits treatment options for this cancer. By priming with a therapeutic vaccine and a low-dose chemotherapy combination ...

Stem cell therapies look promising for heart disease

April 29, 2014
Stem cell therapies work as a complement to standard treatments, potentially cutting the number of deaths after a year, suggests evidence from the latest Cochrane review: Stem cell therapy for chronic ischaemic heart disease ...

Renewed hope for gene therapy in rare disease

July 2, 2014
Between 30 and 40 million people in Europe suffer from rare diseases—many of them children. As most of these diseases have genetic origins, gene therapy is a major hope for their future cure. Until now, however, there ...

Recommended for you

Novel genomic tools provide new insight into human immune system

January 19, 2018
When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host against the intruders. For many decades, ...

Genomics reveals key macrophages' involvement in systemic sclerosis

January 18, 2018
A new international study has made an important discovery about the key role of macrophages, a type of immune cell, in systemic sclerosis (SSc), a chronic autoimmune disease which currently has no cure.

First vaccine developed against grass pollen allergy

January 18, 2018
Around 400 million people worldwide suffer in some form or other from a grass pollen allergy (rhinitis), with the usual symptoms of runny nose, cough and severe breathing problems. In collaboration with the Viennese firm ...

Researchers discover key driver of atopic dermatitis

January 17, 2018
Severe eczema, also known as atopic dermatitis, is a chronic inflammatory skin condition that is driven by an allergic reaction. In their latest study, researchers at La Jolla Institute reveal an important player that promotes ...

Who might benefit from immunotherapy? New study suggests possible marker

January 16, 2018
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

Researchers identify new way to unmask melanoma cells to the immune system

January 16, 2018
system, which enables these deadly skin cancers to grow and spread.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.